{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:12:54Z","timestamp":1790140374831,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473381"],"award-info":[{"award-number":["82473381"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203106"],"award-info":[{"award-number":["82203106"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303748"],"award-info":[{"award-number":["82303748"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172621"],"award-info":[{"award-number":["82172621"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Medical Innovation Research Special Project","award":["21Y11904300"],"award-info":[{"award-number":["21Y11904300"]}]},{"name":"Shanghai Shenkang Research Physician Innovation and Transformation Ability Training Project","award":["SHDC2022CRD035"],"award-info":[{"award-number":["SHDC2022CRD035"]}]},{"name":"the Clinical Research Plan of SHDC","award":["SHDC-2020CR2016B"],"award-info":[{"award-number":["SHDC-2020CR2016B"]}]},{"name":"Shanghai Rising Star Program \u2018Sailing\u2019 Project","award":["22YF1408500"],"award-info":[{"award-number":["22YF1408500"]}]},{"name":"Chinese Urological Cancer Grant","award":["011"],"award-info":[{"award-number":["011"]}]},{"name":"Shanghai Academic\/Technology Research Leader","award":["23XD1420600"],"award-info":[{"award-number":["23XD1420600"]}]},{"name":"the Shanghai Anti-Cancer Association Eyas Project","award":["SACA-CY22A04"],"award-info":[{"award-number":["SACA-CY22A04"]}]},{"name":"the China Urological Oncology Research Foundation"},{"name":"Oriental Scholar Professorship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00259-025-07278-z","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T01:33:55Z","timestamp":1744767235000},"page":"4054-4064","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with \u22645 conventional imaging defined distant metastases"],"prefix":"10.1007","volume":"52","author":[{"given":"Jian","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beihe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-6669","authenticated-orcid":false,"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"338","key":"7278_CR1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.urolonc.2015.05.003","volume":"33","author":"M Afshar","year":"2015","unstructured":"Afshar M, Evison F, James ND, Patel P. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience. Urol Oncol. 2015;33(338):e1-7. https:\/\/doi.org\/10.1016\/j.urolonc.2015.05.003.","journal-title":"Urol Oncol"},{"key":"7278_CR2","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol. 2022;40:3377\u201382. https:\/\/doi.org\/10.1200\/JCO.22.00644.","journal-title":"J Clin Oncol"},{"key":"7278_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147.","journal-title":"JAMA Oncol"},{"key":"7278_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853.","journal-title":"J Clin Oncol"},{"key":"7278_CR5","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3.","journal-title":"Lancet"},{"key":"7278_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","volume":"7","author":"C Greco","year":"2021","unstructured":"Greco C, Pares O, Pimentel N, Louro V, Santiago I, Vieira S, et al. Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial. JAMA Oncol. 2021;7:700\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0039.","journal-title":"JAMA Oncol"},{"key":"7278_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, et al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2022;23:1308\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4.","journal-title":"Lancet Oncol"},{"key":"7278_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","volume":"9","author":"AU Kishan","year":"2023","unstructured":"Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, et al. Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial. JAMA Oncol. 2023;9:365\u201373. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6558.","journal-title":"JAMA Oncol"},{"key":"7278_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"7278_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-023-06556-y","volume":"51","author":"K Akcay","year":"2024","unstructured":"Akcay K, Kibar A, Sahin OE, Demirbilek M, Beydagi G, Asa S, et al. Prediction of clinically significant prostate cancer by [(68) Ga]Ga-PSMA-11 PET\/CT: a potential tool for selecting patients for active surveillance. Eur J Nucl Med Mol Imaging. 2024;51:1467\u201375. https:\/\/doi.org\/10.1007\/s00259-023-06556-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7278_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.euo.2022.02.002","volume":"5","author":"J Pan","year":"2022","unstructured":"Pan J, Wei Y, Zhang T, Liu C, Hu X, Zhao J, et al. Stereotactic radiotherapy for lesions detected via (68)Ga-prostate-specific membrane antigen and (18)F-fluorodexyglucose positron emission tomography\/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study. Eur Urol Oncol. 2022;5:420\u20137. https:\/\/doi.org\/10.1016\/j.euo.2022.02.002.","journal-title":"Eur Urol Oncol"},{"key":"7278_CR12","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41:5561\u20138. https:\/\/doi.org\/10.1200\/JCO.23.00985.","journal-title":"J Clin Oncol"},{"key":"7278_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s44178-024-00118-4","volume":"3","author":"B Dai","year":"2024","unstructured":"Dai B, Wang H, Shi B, Xing J, Zhu S, He Z, et al. CACA guidelines for holistic integrative management of prostate cancer. Holistic Integ Oncol. 2024;3:47. https:\/\/doi.org\/10.1007\/s44178-024-00118-4.","journal-title":"Holistic Integ Oncol"},{"key":"7278_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8:374. https:\/\/doi.org\/10.1038\/s41467-017-00393-y.","journal-title":"Nat Commun"},{"key":"7278_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.prnil.2022.04.005","volume":"10","author":"J Pan","year":"2022","unstructured":"Pan J, Ye D, Zhu Y. Olaparib outcomes in metastatic castration-resistant prostate cancer: first real-world experience in safety and efficacy from the Chinese mainland. Prostate Int. 2022;10:142\u20137. https:\/\/doi.org\/10.1016\/j.prnil.2022.04.005.","journal-title":"Prostate Int"},{"key":"7278_CR16","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med"},{"key":"7278_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.semnuclmed.2021.11.013","volume":"52","author":"A Daryanani","year":"2022","unstructured":"Daryanani A, Turkbey B. Recent advancements in CT and MR imaging of prostate cancer. Semin Nucl Med. 2022;52:365\u201373. https:\/\/doi.org\/10.1053\/j.semnuclmed.2021.11.013.","journal-title":"Semin Nucl Med"},{"key":"7278_CR18","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00259-023-06490-z","volume":"51","author":"M Bauckneht","year":"2024","unstructured":"Bauckneht M, Checcucci E, Cisero E, Rizzo A, Racca M, De Cillis S, et al. The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. Eur J Nucl Med Mol Imaging. 2024;51:864\u201370. https:\/\/doi.org\/10.1007\/s00259-023-06490-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7278_CR19","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00259-016-3415-4","volume":"43","author":"T Van den Wyngaert","year":"2016","unstructured":"Van den Wyngaert T, Strobel K, Kampen WU, Kuwert T, van der Bruggen W, Mohan HK, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43:1723\u201338. https:\/\/doi.org\/10.1007\/s00259-016-3415-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7278_CR20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","volume":"50","author":"WP Fendler","year":"2023","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, et al. PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023;50:1466\u201386. https:\/\/doi.org\/10.1007\/s00259-022-06089-w.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"7278_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.07.020","author":"J Pan","year":"2024","unstructured":"Pan J, Wu J, Wang B, Zhu B, Liu X, Gan H, et al. Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer. Med. 2024. https:\/\/doi.org\/10.1016\/j.medj.2024.07.020.","journal-title":"Med"},{"key":"7278_CR22","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1007\/s00259-023-06123-5","volume":"50","author":"J Pan","year":"2023","unstructured":"Pan J, Zhao J, Ni X, Zhu B, Hu X, Wang Q, et al. Heterogeneity of [(68)Ga]Ga-PSMA-11 PET\/CT in metastatic castration-resistant prostate cancer: genomic characteristics and association with abiraterone response. Eur J Nucl Med Mol Imaging. 2023;50:1822\u201332. https:\/\/doi.org\/10.1007\/s00259-023-06123-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7278_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","volume":"39","author":"IW Deveson","year":"2021","unstructured":"Deveson IW, Gong B, Lai K, LoCoco JS, Richmond TA, Schageman J, et al. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 2021;39:1115\u201328. https:\/\/doi.org\/10.1038\/s41587-021-00857-z.","journal-title":"Nat Biotechnol"},{"key":"7278_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213\u20139. https:\/\/doi.org\/10.1038\/nbt.2514.","journal-title":"Nat Biotechnol"},{"key":"7278_CR25","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1078-0432.CCR-22-2177","volume":"29","author":"AA Davis","year":"2023","unstructured":"Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, et al. Genomic complexity predicts resistance to endocrine therapy and CDK4\/6 inhibition in hormone receptor-positive (HR+)\/HER2-negative metastatic breast cancer. Clin Cancer Res. 2023;29:1719\u201329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2177.","journal-title":"Clin Cancer Res"},{"key":"7278_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN guidelines(R) insights: prostate cancer, version 3.2024. J Natl Compr Canc Netw. 2024;22:140\u201350. https:\/\/doi.org\/10.6004\/jnccn.2024.0019.","journal-title":"J Natl Compr Canc Netw"},{"key":"7278_CR27","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020;383:2345\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2022485.","journal-title":"N Engl J Med"},{"key":"7278_CR28","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1200\/JCO.23.00762","volume":"42","author":"L Kwak","year":"2024","unstructured":"Kwak L, Ravi P, Armstrong JG, Beckendorf V, Chin JL, D\u2019Amico AV, et al. Prognostic impact of prostate-specific antigen at 6 months after radiotherapy in localized prostate cancer: an individual patient data analysis of randomized trials. J Clin Oncol. 2024;42:2132\u20138. https:\/\/doi.org\/10.1200\/JCO.23.00762.","journal-title":"J Clin Oncol"},{"key":"7278_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12885-021-08026-w","volume":"21","author":"J Calais","year":"2021","unstructured":"Calais J, Zhu S, Hirmas N, Eiber M, Hadaschik B, Stuschke M, et al. Phase 3 multicenter randomized trial of PSMA PET\/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. BMC Cancer. 2021;21:512. https:\/\/doi.org\/10.1186\/s12885-021-08026-w.","journal-title":"BMC Cancer"},{"key":"7278_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1186\/s12885-024-12395-3","volume":"24","author":"B Wang","year":"2024","unstructured":"Wang B, Pan J, Zhang T, Ni X, Wei Y, Li X, et al. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy. BMC Cancer. 2024;24:643. https:\/\/doi.org\/10.1186\/s12885-024-12395-3.","journal-title":"BMC Cancer"},{"key":"7278_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37:490\u2013503. https:\/\/doi.org\/10.1200\/JCO.18.00358.","journal-title":"J Clin Oncol"},{"key":"7278_CR32","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1002\/1878-0261.13320","volume":"16","author":"J Pan","year":"2022","unstructured":"Pan J, Zhao J, Ni X, Gan H, Wei Y, Wu J, et al. The prevalence and prognosis of next-generation therapeutic targets in metastatic castration-resistant prostate cancer. Mol Oncol. 2022;16:4011\u201322. https:\/\/doi.org\/10.1002\/1878-0261.13320.","journal-title":"Mol Oncol"},{"key":"7278_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","volume":"608","author":"C Herberts","year":"2022","unstructured":"Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, et al. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022;608:199\u2013208. https:\/\/doi.org\/10.1038\/s41586-022-04975-9.","journal-title":"Nature"},{"key":"7278_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22:26\u201345. https:\/\/doi.org\/10.1038\/s41585-024-00900-z.","journal-title":"Nat Rev Urol"},{"key":"7278_CR35","doi-asserted-by":"publisher","first-page":"175883592312205","DOI":"10.1177\/17588359231220506","volume":"16","author":"J Pan","year":"2024","unstructured":"Pan J, Zhang T, Chen S, Bu T, Zhao J, Ni X, et al. Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study. Ther Adv Med Oncol. 2024;16:17588359231220506. https:\/\/doi.org\/10.1177\/17588359231220506.","journal-title":"Ther Adv Med Oncol"},{"key":"7278_CR36","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.euo.2023.09.006","volume":"7","author":"P Rajwa","year":"2024","unstructured":"Rajwa P, Robesti D, Chaloupka M, Zattoni F, Giesen A, Huebner NA, et al. Outcomes of cytoreductive radical prostatectomy for oligometastatic prostate cancer on prostate-specific membrane antigen positron emission tomography: results of a multicenter European study. Eur Urol Oncol. 2024;7:721\u201334. https:\/\/doi.org\/10.1016\/j.euo.2023.09.006.","journal-title":"Eur Urol Oncol"},{"key":"7278_CR37","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7278_CR38","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35:458\u201372. https:\/\/doi.org\/10.1016\/j.annonc.2024.01.011.","journal-title":"Ann Oncol"},{"key":"7278_CR39","doi-asserted-by":"publisher","unstructured":"Shen H, Liu J, Chen K, Li X. Language model enables end-to-end accurate detection of cancer from cell-free DNA. Brief Bioinform. 2024;25. https:\/\/doi.org\/10.1093\/bib\/bbae053.","DOI":"10.1093\/bib\/bbae053"},{"key":"7278_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41698-024-00635-5","volume":"8","author":"H Shen","year":"2024","unstructured":"Shen H, Yang M, Liu J, Chen K, Li X. Development of a deep learning model for cancer diagnosis by inspecting cell-free DNA end-motifs. NPJ Precis Oncol. 2024;8:160. https:\/\/doi.org\/10.1038\/s41698-024-00635-5.","journal-title":"NPJ Precis Oncol"},{"key":"7278_CR41","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1078-0432.CCR-20-3708","volume":"27","author":"E Warner","year":"2021","unstructured":"Warner E, Herberts C, Fu S, Yip S, Wong A, Wang G, et al. BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression. Clin Cancer Res. 2021;27:1650\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3708.","journal-title":"Clin Cancer Res"},{"key":"7278_CR42","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.euo.2020.12.009","volume":"4","author":"V Conteduca","year":"2021","unstructured":"Conteduca V, Wetterskog D, Gonzalez-Billalabeitia E, Brighi N, De Giorgi U, Attard G. Circulating androgen receptor for prognosis and treatment selection in prostate cancer. Eur Urol Oncol. 2021;4:740\u20134. https:\/\/doi.org\/10.1016\/j.euo.2020.12.009.","journal-title":"Eur Urol Oncol"},{"key":"7278_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamaoncol.2020.5161","volume":"7","author":"K Jensen","year":"2021","unstructured":"Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, et al. Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol. 2021;7:107\u201310. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5161.","journal-title":"JAMA Oncol"},{"key":"7278_CR44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-1943","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Ramesh N, Xu P, Sei E, Hu M, Bai S, et al. Longitudinal profiling of circulating tumor DNA reveals the evolutionary dynamics of metastatic prostate cancer during serial therapy. Cancer Res. 2025. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-1943.","journal-title":"Cancer Res"},{"key":"7278_CR45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","volume":"43","author":"EY Yu","year":"2025","unstructured":"Yu EY, Rumble RB, Agarwal N, Cheng HH, Eggener SE, Bitting RL, et al. Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline. J Clin Oncol. 2025;43:748\u201358. https:\/\/doi.org\/10.1200\/JCO-24-02608.","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07278-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07278-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07278-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T08:10:09Z","timestamp":1756887009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07278-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7278"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07278-z","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study received approval from the institutional review boards of two academic hospitals and adhered to the principles outlined in the Declaration of Helsinki. The requirement to obtain informed consent was waived because of its retrospective design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study has no clinical trial number.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}